Introduction
Sialic acids on cell surface and other glycoconjugates are responsible for a wide variety of biological effects, notably in cell-cell communication (Varki and Schauer 2008; Schauer 2009; Chen and Varki 2010) . These effects are mediated through glycan recognition proteins, particularly the Siglec family (Varki 2007) . Many different forms of sialic acids are known (Varki 1992; Angata and Varki 2002; Schauer 2004) but studies of the effects of sialic acid (Neu5Ac) modifications on the biological properties of sialated glycans have principally focused on modifications to the 5-acetamido group, extension to 2,8-polysialic acid and 9-O-acetylation (Schauer 2009 ). Glycoconjugates with both natural and nonnatural changes to the 5-substituent have been produced in vitro chemi-enzymatically (Yu et al. 2004 (Yu et al. , 2005 Chokhawala et al. 2008; Cao et al. 2009) or in vivo by metabolic incorporation of derivatives of the precursor sugar, ManNAc, with novel amino-group modifications such as an azido function (Prescher and Bertozzi 2006) .
Bacteria produce not only sialic acid but also two other families of nonulosonic acids, based on Legionaminic acid (Leg) and Pseudaminic acid (Pse) (Knirel et al. 2003) . Neither of these occurs as a terminal sugar on glycoconjugates, however. Pse and Leg were first identified in bacterial polysaccharides from Pseudomonas (Knirel et al. 1987) and Legionella (Knirel et al. 1994 ) species. They have since been found in bacterial glycoproteins; derivatives of Pse occur as multiple O-linked monosaccharide modifications on the flagellae of C. jejuni and Helicobacter pylori (Thibault et al. 2001; Schirm et al. 2003; Logan et al. 2009 ), whereas Leg derivatives occur on C. jejuni flagellae (McNally et al. 2007 ). The parent sugar Leg has the same stereochemistry as sialic acid, differing from it at C7 and C9 which have amino and deoxy groups, respectively (Figure 1 ). The Leg modifications at C7 and C9 therefore present a quite different kind of sialic acid analog to the previous C5 and C9 modifications.
The nucleotide-hexose precursor to CMP-Leg5Ac7Ac in L. pneumophila is UDP-4,6-dideoxy-4-acetamido-D-GlcNAc (UDP-N,N′-diacetylbacillosamine, UDP-Bac2Ac4Ac), which is made from UDP-GlcNAc (Glaze et al. 2008) . Previous studies on the genetics of lipopolysaccharide biosynthesis in L. pneumophila implicated the neuC homolog (lpg 0753), the neuB homolog (lpg 0752) and the neuA homolog (lpg 0751) as genes encoding enzymes essential for the biosynthesis of CMP-Leg5Ac7Ac (Luneberg et al. 2000) . Subsequently, it was shown that together these three enzymes are essential components of the pathway that converts UDP-Bac2Ac4Ac into CMP-Leg5Ac7Ac (Glaze et al. 2008) . These enzymes carry out the hydrolysis of the nucleotide and the inversion of the acetamido function at C2 (NeuC), followed by the addition of a three-carbon fragment from phosphoenolpyruvate (NeuB) and finally coupling to CMP (NeuA). This pathway, shown in Figure 2 , differs in its initial steps from the pathway used to produce Leg forms for the modification of flagella in C. jejuni, in which the nucleotide precursor is GDP-Bac2Ac4Ac ).
We have previously characterized the NeuC, NeuB and NeuA enzymes from L. pneumophila (Glaze et al. 2008) , using UDP-Bac2Ac4Ac made with enzymes from the N-glycan locus of C. jejuni (Glover et al. 2005) . We first scaled up the production of CMP-Leg5Ac7Ac by modifying this route. To date, there have been no reports of the identification and biochemical characterization of natural Leg or Pse glycosyltransferases, and only one glycosidase for Pse has been described and structurally characterized (Xu et al. 2009 ). Therefore, in order to introduce Leg5Ac7Ac into glycoconjugates, we tested a series of sialyltransferases from both prokaryotic and eukaryotic sources with CMP-Leg5Ac7Ac as the donor and fluorescent disaccharides as acceptors. We discovered three enzymes that can synthesize Leg5Ac7Ac analogs of the Neu5Ac-α-2,3-T-antigen or of the terminal Gal region that is present in N-linked glycoconjugates. One such fluorescent product based on lactose was then used to characterize the stability of terminal Leg5Ac7Ac residues toward sialidases from viral, bacterial and mammalian sources.
Results and discussion

Enzymatic synthesis of CMP-Leg5Ac7Ac
The central intermediate in the biosynthetic pathway is UDP-Bac2Ac4Ac (Figure 2 ). This was efficiently produced from 100 mg or greater amounts of UDP-GlcNAc by means of C. jejuni dehydratase and aminotransferase enzymes, PglF and PglE, followed by chemical acetylation of the 4-amino group (Glaze et al. 2008) . We also explored the use of an enzyme reactor to produce this compound, created by attaching the His-tagged versions of PglF, PglE and PglD to a small column of an immobilized metal affinity chromatography (IMAC) resin and circulating the substrates through it sequentially at room temperature. UDP-GlcNAc was completely converted to the 4-keto sugar within 8 h; addition of glutamic acid and pyridoxal phosphate led to an equilibrium mixture of 4-keto and 4-amino-UDP-QuiNAc in a ratio of approximately Fig. 1 . Structures of neuraminic acid and legionaminic acid, in their N-acetylated forms. Leg is 5,7-diamino-3,5,7,9-tetradeoxy-D-glycero-Dgalacto-non-2-ulosonic acid. Fig. 2 . Synthesis of CMP-Leg5Ac7Ac. The PglF, PglE and PglD enzymes were from C. jejuni; their putative gene equivalents in L. pneumophila are lpg0966, lpg0755 and lpg0754, respectively. The NeuA, NeuB and NeuC enzymes were from the L. pneumophila genes lpg0751, lpg0752 and lpg0753, respectively (Glaze et al. 2008) . The replacement steps used in the in vitro synthesis are shown in parentheses below the arrows.
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1:2. Upon the addition of Ac-CoA, almost complete conversion to Bac2Ac4Ac occurred in 8 h, i.e. the remaining keto product had been converted to amino sugar as the pool of this compound was being acetylated. While this process is an attractive one, it requires the relatively expensive substrate Ac-CoA.
Cloning and expression of Legionella NeuC, which encodes a hydrolyzing UDP-Bac2Ac4Ac 2-epimerase ( Figure 2 ) and of Legionella NeuA, which encodes the CMP-Leg5Ac7Ac synthetase, resulted in high yields of active soluble protein. However, cloning and expression of NeuB resulted in insoluble protein which was found to possess very low levels of Leg5Ac7Ac synthase activity (data not shown). Expression of NeuB as a fusion protein C-terminal to the MalE protein of Escherichia coli resulted in more soluble protein which was also inactive (data not shown). We therefore adapted the synthetic pathway to use the E. coli sialic acid aldolase NanA for the condensation reaction with pyruvate as a replacement for NeuB and the more expensive phosphoenol pyruvate substrate (Figure 2 ). Incubation of UDP-diacetylbacillosamine with NeuC enzyme resulted in the hydrolysis/epimerization reaction being complete within 3 h at 37°C pH 7.5 as judged by CE analysis. Monitoring of the CE trace at 260 nm indicated the absence of any residual UDP-Bac2Ac4Ac and the appearance of free UDP. The latter was removed from the reaction mixture by anion exchange chromatography as a precautionary measure to ensure that it would not exert any inhibitory effects upon downstream synthesis, and negative-ion electrospray ionization mass spectrometry confirmed that the product was a diacetamido-2,4,6-trideoxyhexose (m/z 245 [M-H] − ). To drive the NanA aldolase reaction toward the formation of condensation product, pyruvate was used in an excess amount and the formation of Leg5Ac7Ac was confirmed by negative-ion capillary electrophoresis mass spectrometry (CE-MS) (m/z 333 [M-H] − ). Incubation of the nonulosonic acid with CTP, MgCl 2 and NeuA resulted in the formation of CMPLeg5Ac7Ac as judged by CE and CE-MS (m/z 638 [M-H] − ). This reaction was sensitive to the final concentration of CTP in the reaction mixture. The optimal concentration was between 0.5 and 1.0 mM; concentrations above or below this range resulted in a severe decline in the quantitative formation of the CMP product. Following purification by anion exchange chromatography, CMP-Leg5Ac7Ac was quantitated spectrophotometrically. Starting from 50 mg of UDPBac2Ac4Ac, the three-step chemo-enzymatic synthesis gave a yield of 28 mg for an overall yield of 54% on a molar basis.
Since Leg5Ac7N might provide a useful starting point for the synthesis of further Sia analogs, we tested the PglE product, Bac2NAc4N, its 4N trifluoroacetate derivative ( prepared by reaction with trifluoracetic anhydride) and 4N azido derivative ( prepared by reaction with imidazole-1-sulfonyl azide hydrochloride) with Lp NeuC. None of these compounds could be successfully converted to the corresponding 4-amino-6-deoxy-ManNAc form; at high enzyme concentrations, some of the putative glycal intermediate in the hydrolysis/inversion process was formed.
Sialyltransferases can utilize CMP-Leg5Ac7Ac
In order to evaluate the ability of sialyltransferases to utilize the CMP-Leg5Ac7Ac donor, we selected enzymes from all four carbohydrate-active enzymes database (CAZy) families of well-characterized sialyltransferases (Table I) . Bacterial sialyltransferases are found in the CAZy families GT-42, GT-52 and GT80, whereas the mammalian sialyltransferases are all in CAZy family GT-29 (Cantarel et al. 2009 ). Out of the eight sialyltransferases tested from these enzyme families, including ones specific for α2,3 or α2,6 and α2,8 linkages, only two had a strong activity with CMP-Leg5Ac7Ac as the donor. These were the CAZy family GT-80 sialyltransferase from P. multocida, whose natural acceptors are not known, and the porcine family GT-29 enzyme, ST3Gal1, which is part of the protein O-linked glycosylation pathway and modifies Galβ1,3GalNAc groups at the 3-OH of the Gal. Remarkably, both the successful enzymes were highly active, with CMP-Leg5Ac7Ac showing 60% of the kcat donor activity of CMP-Neu5Ac, with the Lac-FCHASE (6-(fluorescein-5-carboxyamido)-hexanoic acid succinimidyl ester derivative of the p-aminophenyl glycoside) acceptor in the case of the P. multocida and with the T-antigen acceptor for the ST3Gal1. The data from kinetic characterizations of these reactions are shown in Table II . The porcine enzyme had much higher activity than the P. multocida enzyme, but in our hands it has shown lower stability. Hence, both enzymes have their merits for producing Leg-glycoconjugates.
The α2,3 linkage of the Leg5Ac7Ac to the lactose moiety of the fluorescent acceptor ( Figure 3 ) was confirmed by proton NMR; in particular, the chemical shift of the Gal H3 matched that reported for the Neu5Ac homolog (Gilbert et al. 2000) and the chemical shifts of the Gal H6 protons were unchanged from those in the lactose substrate. An interesting pH profile has been reported for the P. multocida GT-80 enzyme, in which it switched from forming α2,3 Neu5Ac Glycoconjugates with legionaminic acid residues linkages to Gal at pH 8 to α2,6 linkages at pH 5 (Yu et al. 2005 ). However, we did not see this shift with the acceptors we used here. Instead, the reactivity with CMP-Leg5Ac7Ac and the T-antigen acceptor increased as the pH was lowered and with the lactose acceptor to a lesser degree (Figure 4 ). The products formed at various pHs were identical, based on the mobility in both CE and TLC analyses. The P. multocida enzyme was able to transfer Leg5Ac7Ac either to a semi-synthetic biantennary N-glycan or to an asialoglycopeptide mixture from transferrin. The synthetic glycopeptide was 94% converted to the di-Leg5Ac7Ac compound in a 1 h reaction at 30°. A third sialyltransferase, the GT-80 α2,6 enzyme from Photobacterium sp., was more weakly active, with Galβ1,4GlcNAc (LacNAc)-FCHASE as the acceptor, and its specific activity with CMP-Leg5Ac7Ac as the donor was 6.3% of that with CMP-Sia (0.39 vs. 6.43 U/mg). It also was able to transfer Leg5Ac7Ac to the biantennary glycan. The sialyltransferases C. jejuni Cst-I and Cst-II (GT-42), Neisseria meningitidis Lst GT-52 and human ST6Gal1 (also showed no activity with CMP-Leg5Ac7Ac, regardless of the acceptor used for the assay.
Comparison of the behavior of the tested sialyltransferases with the crystal structures reported for some of them suggested a general correlation of Leg activity with the involvement of the C7-C9 glycerol element in their recognition of sialic acid analogs. Thus, the structure of the P. multocida enzyme, PDB 21HZ reported by Ni et al. (2006) , shows only limited interaction in this region, e.g. a H-bond between the C7 hydroxyl and Trp270 ( Figure 5A ), suggesting that it can accommodate various modifications in the glycerol part. Its promiscuity is remarkable as it has been previously shown to tolerate substitutions on the C5 acetamido group as well (Yu et al. 2005) . In contrast, other sialyltransferases that were inactive with CMP-Leg5Ac7Ac showed multiple interactions with the C7-C9 region, for example, in the C. jejuni Cst-I, PDB code 2P2V (Chiu et al. 2007 ), Asn66 and Gln47 form hydrogen bonds with O7, O8 and O9.
Terminal Leg5Ac7Ac groups are resistant to sialidases In contrast to the considerable activity of the above two sialyltransferases with the Leg5Ac7Ac donor, sialidases were much Fig. 3 . Structure of the α2,3-Leg5Ac7Ac-lactose-FCHASE product. less effective on a Leg5Ac7Ac substrate compared with its Neu5Ac equivalent. Six sialidases from bacterial, viral or mammalian sources were tested with Leg5Ac7Ac-α2, 3-lactose-FCHASE as a substrate in comparison to Neu5Ac-α2,3-lactose-FCHASE. All showed several orders of magnitude less activity than with the native substrate (Table III) . None of the sialidases had activities with the Leg5Ac7Ac substrate compared with Neu5Ac that at all resembled the levels of the two active sialyltransferases with the two donors. The best (or rather, least bad) enzyme was influenza neuraminidase N1 and the lowest potency was shown by the human NEU2 enzyme. They differ by 100-fold, suggesting that sialidase inhibitors based on legionaminic acid could show considerable selectivity for the viral enzyme over the human one.
Similar to the behavior of the sialyltransferases, the structures of the sialidases (see Table III for their PDB entries) showed some correlations of activity with the degree of involvement of the glycerol moiety in substrate recognition. The more active ones, the influenza N1 and Micromonospora Fig. 5 . The active site regions of sialyltransferases, sialidases and Siglecs. P. multocida and CstI sialyltransferases with bound CMP-3F-Neu5Ac (Ni et al. 2006; Chiu et al. 2007 ); C. perfringens sialidase with bound Neu5Ac (Newstead et al. 2008) and influenza virus N1 with bound zanamivir ); Siglec 7 with the terminal Neu5Ac of diasialyl-lactose (Alphey et al. 2003 ) and sialoadhesin, Siglec 1, with the Neu5Ac of sialyl-lactose (May et al. 1998 ). The figure was prepared with the PyMOL Molecular Graphics System (version 1.2r3pre, Schrödinger, LLC).
Glycoconjugates with legionaminic acid residues viridifaciens enzymes, form H-bonds to the C8 and C9 hydroxyls of Neu5Ac or its analogs through single residues, Glu276 and Asp259, respectively (Gaskell et al. 1995; Xu et al. 2008) , and the Clostridium perfringens enzyme interacts at C9 with Gln493 and at C9 and C8 through water molecules (Newstead et al. 2008) (Figure 5B ). The C7 hydroxyl in these enzymes does not interact through H-bonds at all. The next weakest, the Salmonella typhi enzyme, employs a network of H-bonds to all three hydroxyls from the side chains of Ser230 and Trp128 and from water molecules (Crennell et al. 1996) . The enzyme from the Newcastle disease virus also has an extensive H-bond network around the C7-C9 hydroxyls, mainly arising from interactions of Glu258 with the C7 and C9 hydroxyls (Ryan et al. 2006) . The weakest of all, NEU2, has the most extensive network of side chain interactions involving four different residues, Glu111, Tyr179, Tyr181 and Arg237 (Chavas et al. 2005) . These sialidases belong to three different CAZy GH families (Table III) but their activities with Leg5Ac7Ac compounds were not correlated with the GH family.
Synthesis of leg glycoconjugates
Our experience with the P. multocida sialyltransferase suggests that this enzyme will be capable of making small Leg5Ac7Ac glycoconjugates analogous to the terminal segments of O-or N-linked glycans as the donor. However, although this enzyme would modify biantennary N-glycan samples, it would not modify larger acceptors such as asialotransferrin. Despite its much weaker activity with the CMP-Leg5Ac7Ac donor, the Photobacterium sialyltransferase may be applicable to this type of acceptor. In contrast, the porcine ST3Gal1 enzyme is known to sialylate glycoproteins with O-linked glycans, and it should be able to form their Leg5Ac7Ac analogs. Among other possible biological effects, we expect that the Leg5Ac7Ac modification would favorably impact the half-life of such glycoproteins in vivo, since sialic acid is known to be a determinant of protein half-life, including protein therapeutics (Elliott et al. 2004; Walsh and Jefferies 2006) . For this type of application, the immunogenicity of Leg5Ac7Ac would need to be determined, of course. The possible interaction of Leg5Ac7Ac with the main group of sialic acid recognition proteins, the Siglecs (Crocker et al. 2007 ) is not predictable, judging from the above data on sialidases. The available crystal structures for complexes of Siglec 1 (sialoadhesin) (PDB code 1QFO; May et al. 1998 ) and Siglec 7 (PDB code 2DFR; Alphey et al. 2003 ) with sialic acid compounds ( Figure 5C ) show H-bonding of the C9 hydroxyl of Neu5Ac with the peptide backbone (of Leu107 and Asn133, respectively), but the C7 hydroxyl is not H-bonded. Although the H-bond to the C9 hydroxyl would be lost in an interaction with Leg5Ac7Ac, the hydrophobic interaction of a nearby Trp (Trp106 and Trp132, respectively) with C9 could be well enhanced.
Materials and methods
Bacterial strains and plasmids P. multocida strain P-1059 (ATCC 15742) was grown on chocolate agar at 37°C. E. coli AD202 (CGSC# 7297) was used as the host strain for cloning and overexpression experiments. The plasmid pCW and a version with the malE gene for protein fusions were used as cloning/expression vectors (Bernatchez et al. 2007 ) for the sialyltransferases and two of the sialidases used in this study. Details of various sialyltransferases are given in Table I .
Cloning, overexpression and purification of E. coli sialic acid aldolase (NanA) and P. multocida sialyltransferase (PM0188h) The nanA gene, GenBank accession number AP_003767.1, and PM0188 homolog, GenBank accession number NP_245125.1, were obtained from the chromosomes of E. coli strain AD202 and P. multocida strain P-1059, respectively, by PCR amplification with Phusion DNA polymerase (New England Biolabs Inc., Ipswich, MA) according to the manufacturers instructions. The primers used incorporated either Nde1 or Sal1 cloning sites (underlined) and a 6X His tag (italics) in the 3′ PCR primer. The primer pairs used were: 5′-CTAGCTAGCTAGCATATGGCAACGAATTTACGTGGCG TAATGGC-3′ (forward primer) and 5′-CTAGCTAGCTAG GTCGACTTATTAGTGATGGTGATGGTGATGCCCGCGCTC TTGCATCAACTGCTGG-3′ (reverse primer) for nanA and 5′-CTAGCTAGCTAGCATATGTCAAAAACAATCACGCTGT ATTTAGATCC-3′ (forward primer) and 5′-CTAGCTAGCT AGGTCGACTTATTAGTGATGGTGATGGTGATGCAACTGT TTTAAACTGTCCCAAAAG-3′ (reverse primer) for PM0188h. The PCR products were gel purified and cloning sites generated by double digestion with Nde1 and Sal1 restriction enzymes according to the manufacturers suggested protocol (New England Biolabs Inc.). Cells from positive clones, as judged by sequence analysis, were grown at 37°C in 1 L of 2YT media supplemented with 150 μg/mL ampicillin. Overexpression of NanA and PM0188h was induced through the addition of 1 mM isopropyl β-D-thiogalactopyranoside at an A 600 of 0.4 and growth continued for 6 h at 37°C. Cells were harvested by centrifugation at 10,000 × g for 15 min, resuspended in 10 mM HEPES buffer pH 7.5 containing protease inhibitor cocktail (Roche Diagnostics, Laval, QC) and lyzed by mechanical disruption with an Avestin C5 Emulsiflex cell disrupter (Avestin, Ottawa, ON). The cell lysate was clarified by centrifugation at 27,000 × g for 30 min and cell debris discarded. Soluble protein fractions were obtained from clarified cell extracts by centrifugation at 100,000 × g for 60 min. Following adjustment to 500 mM NaCl and 50 mM imidazole, the soluble protein fraction was loaded directly onto a 5 ml HisTrap™ column (GE Healthcare Biosciences, Baie D'Urfé, QC) previously equilibrated with 10 mM HEPES pH 7.5, 500 mM NaCl, 50 mM imidazole. NanA or Pm0188h were eluted using a linear gradient of 50-500 mM imidazole in 10 mM HEPES pH 7.5, 500 mM NaCl and fractions containing protein of interest, as judged by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), were pooled and dialyzed against 500 mM NaCl and 10 mM HEPES pH 7.5.
Additional enzymes
The cloned bacillosamine pathway genes from C. jejuni and the legionaminic acid pathway genes from L. pneumophila have been previously described (Glaze et al. 2008 ). The sialyltransferases C. jejuni Cst I and Cst II, N. meningitidis Lst, Pst and porcine ST3Gal1 were expressed from genes previously cloned in our laboratories (Gilbert et al. 1996 (Gilbert et al. , 2000 Willis et al. 2008; Rao et al. 2009 ) and the human ST6Gal1 was purchased from Calbiochem, EMD Biosciences, La Jolla, CA. A synthetic gene for the Photobacterium sp. JT-ISH-224 Sialyltransferase, GenBank accession number AB293985.1, without residues 1-109 and expression optimized (Blue Heron Biotechnology, Bothwell, WA), was made as a C-terminal fusion to the E. coli maltose-binding (MalE) protein in the pCW vector as previously described (Gilbert et al. 2002; Bernatchez et al. 2007 ). More information on these transferases is given in Table I . Sialidases from S. typhi and C. perfringens were obtained from New England Biolabs, Newcastle disease virus neuraminidase was from Prozyme (Hayward CA) and influenza virus neuraminidase N1 was from R&D Systems (Minneapolis, MN); M. viridifaciens sialidase was produced from a clone provided by Dr. Andrew Bennet. More information on these glycohydrolases is given in Table III .
MalE-NEU2 neuraminidase fusion protein
The human NEU2 gene, GenBank accession number BC069151.1, was synthesized as a full-length 1155 bp fragment incorporating 5′ Nde1 and 3′ Sal1 cloning sites (GenScript Corporation, Piscataway, NJ). The cloned synthetic gene was subcloned into pCW malE vector (Bernatchez et al. 2007 ). Overexpression of human NEU2 was induced through the addition of isopropyl β-D-thiogalactopyranoside to a final concentration of 1 mM at an A 600 of 0.4 and growth continued for a further 16 h at 20°C. Cells were harvested by centrifugation at 10,000 × g for 15 min, resuspended in 200 mM NaCl, 20 mM Tris pH 7.5 and 1 mM ethylenediaminetetraacetic acid (EDTA) containing protease inhibitor cocktail (Roche) and lyzed by mechanical disruption. The MalE fusion protein was purified from a 100,000 × g supernatant on Amylose resin as suggested by New England Biolabs. Fractions containing the protein of interest, as judged by SDS-PAGE, were pooled and dialyzed against 200 mM NaCl and 20 mM TrisHCl ( pH 7.5). Contaminating endogenous MalE was removed by size exclusion chromatography using tandem Superose 12 10/300 GL columns (GE Healthcare) equilibrated in 200 mM NaCl and 20 mM Tris-HCl ( pH 7.5). Homogeneity of >95% was achieved by size-exclusion chromatography as judged by SDS-PAGE.
Glycoconjugate acceptors
Fluorescent derivatives of lactose, T-antigen, Galβ1,4GlcNAcβ and α2,8-NeuAc-α2,3-NeuAc-lactose with the FCHASE group were prepared as described (Bernatchez et al. 2007; Willis et al. 2008) . The structure of the lactoside acceptor after modification with Leg5Ac7Ac is shown in Figure 3 . The biantennary glycopeptides of transferrin were prepared by double pronase digestion of the protein and purified by gel-filtration on a BioGel P2 column. Mass spectrometry confirmed that only one or two amino acid residues remained attached to the glycan. The glycopeptide was de-sialylated with the C. perfringens sialidase (New England Biolabs) and labeled at the N-terminal amino group with a fluorescent tag. A semi-synthetic form of the asialobiantennary-Asn structure labeled with FMOC (Kajihara et al. 2010 ) was also used.
Enzymatic synthesis of UDP-Bac2Ac4Ac
This was prepared from UDP-GlcNAc by means of the C. jejuni PglF and PglD enzymes followed by chemical acetylation of the 4-amino group, as described by Glaze et al. (2008) , except that the product was purified by ion exchange on HiPrep™ Q FF (GE Healthcare). An enzyme reactor approach (Nahalka et al. 2003) was also tested for making Bac2Ac4Ac. Aliquots of 1 mg each of the His 6 -tagged versions of PglF, PglE and PglD were applied to a 1 mL IMAC column (GE Healthcare), which was then washed with HEPES buffer 25 mM pH 7.5 containing 0.01% NaN 3 , at 0.5 mL/min. Sequential reactions with the three substrates were then made, beginning with 5 mg of UDP-GlcNAc in 4 mL of buffer, followed after overnight reaction at room temperature by the addition of L-Glu to 12.5 mM and pyridoxal phosphate to 40 μM and, after a further 17 h, Ac-CoA to 1.9 mM. Samples of the reaction mixture were taken at various times and examined by CE (see CE and CE-MS analysis section).
Enzymatic synthesis of CMP-Leg5Ac7Ac
An aliquot (2 mg) of freshly prepared L. pneumophila NeuC in 25 mM Na 2 HPO 4 pH 7.5 was added to a solution containing 50 mg of UDP-Bac2Ac4Ac dissolved in 25 mM Na 2 HPO 4 pH 7.5 (final volume of 10 mL) and the solution incubated at 37°C for 3 h. Once the reaction was complete, as judged by CE analysis and negative-ion CE-MS mass spectra, the enzyme was removed by centrifugal ultrafiltration. To remove the UDP, the filtrate was passed through a 20 mL column of AG1-X2 resin (200-400 mesh, acetate form) and eluted with H 2 O. The flow-through was concentrated under
Glycoconjugates with legionaminic acid residues reduced pressure to a final volume of 10 mL, lyophilized and reconstituted in 100 mM Tris-HCl pH 8.5, 25 mM sodium pyruvate, 25 mM MgCl 2 . Freshly prepared NanA (2 mg), in 100 mM Tris-HCl pH 8.5 was added and the reaction mixture incubated at 25°C for 48 h. NanA was removed by centrifugal ultrafiltration and the reaction mixture analyzed for Leg5Ac7Ac by negative-ion CE-MS (m/z 333 [M-H] − ). L. pneumophila NeuA (4 mg) in 100 mM Tris-HCl pH 8.5 and cytidine 5′-triphosphate (1 mM) were added to the Leg5Ac7Ac reaction mixture. After incubation at 37°C for 4 h, precipitated Mg 2+ pyrophosphate was removed by centrifugation at 10,000 rpm for 15 min, the enzyme was removed by centrifugal ultrafiltration and the mixture monitored for CMP-Leg5Ac7Ac production by CE and negativemode CE-MS (m/z 638 [M-H] − ). The reaction product was diluted 15-fold with H 2 O and loaded onto a 5 mL HiTrap™ Q FF anion exchange column (GE Healthcare Biosciences) at a flow rate of 2 mL/min. The column was washed with 5 column volumes of H 2 O and eluted with a linear gradient of 0-125 mM NH 4 HCO 3 over 20 column volumes. The eluate was monitored at A 254 and UV absorbing fractions analyzed by CE and negative-mode CE-MS. Fractions containing purified CMP-Leg5Ac7Ac were pooled, concentrated under reduced pressure, reconstituted in H 2 O and concentrated under reduced pressure a further two times followed by lyophilization. The product was quantitated spectrophotometrically using the molar extinction coefficient of CMP ε 262 = 7400 M −1 cm −1
.
CE and CE-MS analysis
CE analysis was performed using a P/ACE MDQ system equipped with either diode array detection or with a Laser module 488 (Beckman Coulter, Fullerton, CA). Capillaries were bare silica 50 μm × 50 cm with a detector at 50 cm. For diode array detection, the running buffer was 25 mM sodium tetraborate, pH 9.4, and separations were performed at 27 kV for 20 min. For laser-induced fluorescence detection, the running buffer used was 91 mM Tris/91 mM borate/2 mM EDTA, pH 8.8, and samples were run at 30 kV for 15 min. Samples were introduced by pressure injection for 10 s and quantification performed by integration of trace peaks using the MDQ 32 Karat software. CE-MS was performed using a Prince CE system (Prince Technologies, The Netherlands) coupled to a 4000 QTRAP mass spectrometer (Applied Biosystems/MDX Sciex, Concord, ON). Separations were obtained on a 90 cm bare silica capillary using 30 mM morpholine in deionized water, pH 9. A separation voltage of 20 kV, together with a pressure of 500 mbar, was used for fast CE-MS analysis. The −5.2 kV electrospray ionization was used for negative-ion mode detection.
Screening of sialyltransferases
Primary screening of the enzymes was carried out with Lac-FCHASE, LacNAc-FCHASE and T-antigen-FCHASE as acceptors, and CMP-Leg5Ac7Ac and CMP-Neu5Ac as donors. The buffer conditions were taken from the references cited in Table I . Assays were performed at 30°C for 60 min using final concentrations of 200 μM FCHASE labeled substrate and 1 mM donor substrate in a total reaction volume of 10 μL. Reactions were stopped by the addition of 10 μL of 50% acetonitrile, 10 mM EDTA, 1% SDS. Reactivity was assessed by thin-layer chromatography on silica using a solvent system of ethylacetate/methanol/water/acetic acid 4:2:1:0.1. Those reactions that showed product formation were then quantified by capillary electrophoresis using laserinduced fluorescence as described previously (Wakarchuk and Cunningham 2003) . For the active enzymes, more complete kinetic analyses were carried out over a range of concentrations of donor (50 μM to 1 mM) and acceptor (50 μM to 3 mM) using the CE-based assay as previously described (Gilbert et al. 1997) . The pH profiles of reactions of the P. multocida sialyltransferase with the above donors and acceptors were obtained with 50 mM sodium acetate buffer pH 5.5, 50 mM 2-(N-morpholino)ethanesulfonic acid (MES) buffers pH 6.0 and 6.5 and 50 mM Tris buffers pH 7.5, 8.5 and 9.5, each with 5 mM MgCl 2 . After 30 min at 30°C, the reactions were stopped and analyzed by CE as above. FCHASE-labeled asialotransferrin glycopeptide and FMOC-labeled asialobiantennary N-glycan (Kajihara et al. 2010) were also tested as substrates with the P. multocida and the Photobacterium sp. sialyltransferases. A typical reaction mixture (10 μL of 0.1 M Tris buffer pH 8.5) containing 0.5 mM FMOC-N-glycan, 7 mM CMP-Leg5Ac7Ac or CMP-Neu5Ac, 5 mm MgCl 2 and 3 μg P. multocida sialyltransferase was incubated for 1 h at 30°; the mixture was then diluted with 40 μL of water and examined by TLC and CE.
Reactivity of Leg5Ac7Ac-Lac-FCHASE with sialidases
The Leg5Ac7Ac derivative of lactose-FCHASE was made on a mg scale by the method previously described for the Neu5Ac derivative (Gilbert et al. 1997 ) except that the P. multocida sialyltransferase was used instead of the N. meningitidis enzyme. For the present work, the Neu5Ac homolog was made with the C. jejuni Cst-I enzyme (Gilbert et al. 2000) .The structure of the Leg5Ac7Ac product was confirmed as the α2,3 compound by 600 MHz proton NMR, by comparison with the fully assigned spectrum of the Neu5Ac derivative of lactose-FCHASE (Gilbert et al. 2000) . Cleavage of the Leg5Ac7Ac or Neu5Ac groups from these compounds by the sialidases (Table III) was determined with 100 μM substrate concentrations in 10 μL volumes, using the buffers supplied with the commercial enzymes from S. typhimurium, C. perfringens, Newcastle disease virus and influenza virus. The human NEU2 sialidase reactions were performed in 50 mM NaOAc pH 5.6 and the M. viriditaciens sialidase reactions in 50 mM MES pH 6.0. After incubation at 37°C for 1 h, the reactions were stopped and analyzed by capillary electrophoresis, as above.
